What is the protocol for transitioning a patient from warfarin to a therapeutic heparin (unfractionated heparin) drip?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 1, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Transitioning from Warfarin to Therapeutic Heparin Drip

When transitioning from warfarin to a therapeutic heparin drip, discontinue warfarin and initiate full-dose intravenous heparin without delay, with no need to wait for the INR to normalize before starting heparin therapy.

Protocol for Transition

Step 1: Discontinue Warfarin

  • Stop warfarin administration immediately
  • No need to administer vitamin K to reverse warfarin's effect unless there is active bleeding or an emergent procedure

Step 2: Initiate Therapeutic Heparin Infusion

  • Start with an initial bolus of 80 units/kg IV 1
  • Follow with a continuous infusion at 18 units/kg/hour 1
  • For a 70 kg adult, this translates to approximately:
    • 5,600 units IV bolus
    • 1,260 units/hour continuous infusion

Step 3: Monitor and Adjust Heparin Therapy

  • Check aPTT 4-6 hours after the initial bolus 1
  • Adjust the infusion rate to maintain aPTT at 1.5-2.5 times control value (approximately 45-75 seconds) 2
  • After any dose change, recheck aPTT in 6-10 hours 2
  • Once aPTT is in therapeutic range, monitor daily 2

Important Considerations

Effect of Residual Warfarin on aPTT

  • Warfarin affects both INR and aPTT measurements 3
  • For each 1.0 increase in INR, the aPTT increases approximately 16 seconds 3
  • The effects of warfarin and heparin on aPTT are additive 3
  • This may lead to falsely elevated aPTT readings while warfarin is still active in the system

Monitoring Recommendations

  • Be aware that initial aPTT values may be elevated due to residual warfarin effect
  • Consider measuring both aPTT and anti-Factor Xa levels if available, especially during the first 24-48 hours of transition
  • Anti-Factor Xa levels (0.35-0.70) provide a more accurate assessment of heparin activity when warfarin effect is still present 3

Special Patient Populations

  • For patients at high risk of thromboembolism (mechanical heart valves, recent thrombosis):
    • Ensure no gap in anticoagulation coverage
    • Start heparin immediately upon warfarin discontinuation 2
  • For elderly patients or those with renal impairment:
    • Consider using a lower initial bolus (60 units/kg) and infusion rate (12 units/kg/hour)
    • Monitor more frequently for signs of bleeding

Common Pitfalls to Avoid

  1. Waiting for INR to normalize before starting heparin

    • This creates a dangerous gap in anticoagulation coverage
    • Heparin should be started immediately when transitioning from warfarin
  2. Reducing heparin dose based solely on elevated aPTT during transition

    • May result in subtherapeutic heparin levels due to warfarin's effect on aPTT 3
    • Consider anti-Factor Xa levels for more accurate heparin dosing during transition
  3. Failing to account for patient-specific factors

    • Adjust dosing for extremes of weight, renal function, and bleeding risk
    • Higher vigilance needed for patients with recent surgery or procedures
  4. Inadequate monitoring during transition

    • The first 24-48 hours require closer monitoring of coagulation parameters
    • Watch for signs of bleeding or thrombosis during this period

By following this protocol, you can ensure a safe and effective transition from warfarin to therapeutic heparin while maintaining adequate anticoagulation and minimizing risks of both thrombosis and bleeding.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.